Article Text

Download PDFPDF

Raised CRP levels mark metabolic and functional impairment in advanced COPD
  1. R Broekhuizen1,
  2. E F M Wouters1,
  3. E C Creutzberg2,
  4. A M W J Schols1
  1. 1Department of Respiratory Medicine, University Hospital Maastricht, The Netherlands
  2. 2Asthma Centre Hornerheide, Horn, The Netherlands
  1. Correspondence to:
    Dr R Broekhuizen
    Department of Respiratory Medicine, University Hospital Maastricht, P O Box 5800, 6202 AZ Maastricht, The Netherlands; r.broekhuizen{at}pul.unimaas.nl

Abstract

Background: C-reactive protein (CRP) is often used as a clinical marker of acute systemic inflammation. Since low grade inflammation is evident in chronic diseases such as chronic obstructive pulmonary disease (COPD), new methods have been developed to enhance the sensitivity of CRP assays in the lower range. A study was undertaken to investigate the discriminative value of high sensitivity CRP in COPD with respect to markers of local and systemic impairment, disability, and handicap.

Methods: Plasma CRP levels, interleukin 6 (IL-6) levels, body composition, resting energy expenditure (REE), exercise capacity, health status, and lung function were determined in 102 patients with clinically stable COPD (GOLD stage II–IV). The cut off point for normal versus raised CRP levels was 4.21 mg/l.

Results: CRP levels were raised in 48 of 102 patients. In these patients, IL-6 (p<0.001) and REE (adjusted for fat-free mass, p = 0.002) were higher while maximal (p = 0.040) and submaximal exercise capacity (p = 0.017) and 6 minute walking distance (p = 0.014) were lower. The SGRQ symptom score (p = 0.003) was lower in patients with raised CRP levels, as were post-bronchodilator FEV1 (p = 0.031) and reversibility (p = 0.001). Regression analysis also showed that, when adjusted for FEV1, age and sex, CRP was a significant predictor for body mass index (p = 0.044) and fat mass index (p = 0.016).

Conclusions: High sensitivity CRP is a marker for impaired energy metabolism, functional capacity, and distress due to respiratory symptoms in COPD.

  • BMI, body mass index
  • COPD, chronic obstructive pulmonary disease
  • CRP, C-reactive protein
  • FFMI, fat-free mass index
  • FM, fat mass
  • FEV1, forced expiratory volume in 1 second
  • FVC, forced vital capacity
  • Pao2, arterial oxygen tension
  • Paco2, carbon dioxide tension
  • RER, respiratory exchange ratio
  • Tlco, carbon monoxide transfer factor
  • e, ventilation
  • o2, oxygen consumption
  • co2, carbon dioxide production
  • C-reactive protein
  • chronic obstructive pulmonary disease
  • systemic inflammation
  • exercise capacity
  • health status
  • interleukin 6
View Full Text

Statistics from Altmetric.com

Footnotes

  • Published Online First 29 July 2005

  • Supported by GlaxoSmithKline.

  • Competing interests: EFMW serves as a consultant to GlaxoSmithKline (GSK) and is a member of the scientific advisory board for GSK. He received lecture fees and research grants between 2001 and 2004 from GSK. None of the other authors has any conflict of interest to disclose.

  • Written informed consent was obtained from all subjects and the ethical review board of the University Hospital Maastricht approved the study.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Airwaves
    Wisia Wedzicha